The Business Research Company’s report on the Liver Cancer Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the liver cancer market further?
The increase in alcohol consumption is expected to propel the growth of the liver cancer market going forward. Alcohol consumption refers to the intake of alcoholic beverages, typically measured in terms of quantity and frequency. People are increasingly consuming alcohol because it helps them unwind from daily stress, fosters social connections in gatherings, and enhances moments of relaxation, while also being widely promoted through media and becoming more accessible in various settings. Excessive alcohol consumption can lead to liver cirrhosis, inflammation, and DNA damage, increasing the risk of liver cancer by promoting abnormal cell growth. For instance, in March 2023, according to the National Drugs Library, an Ireland-based data collection organization, in 2022, the average alcohol consumption for individuals over 15 years old rose to 10.2 liters of pure alcohol per capita, reflecting a 7.6% increase from 2021. Therefore, increasing alcohol consumption drives the liver cancer market.
Access Your Free Sample of the Global Liver Cancer Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22039&type=smp
What are the key factors influencing the forecasted market size of the liver cancer industry?
The liver cancer market size has grown rapidly in recent years. It will grow from $2.94 billion in 2024 to $3.37 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to rising global incidence of liver cancer, increasing prevalence of hepatitis B and C infections, growing rates of non-alcoholic fatty liver disease, government initiatives promoting early diagnosis, rising awareness about liver health.
The liver cancer market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2029 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to growing geriatric population, increased healthcare expenditure, rising demand for minimally invasive treatments, growing number of specialty clinics, rising medical tourism. Major trends in the forecast period include advancements in diagnostic technologies, development of targeted therapies, introduction of combination therapies, technological advancements in surgical procedures, advancements in radiotherapy techniques.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22039&type=smp
Who are the leading competitors in the liver cancer market?
Major companies operating in the liver cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Terumo Corporation, Eisai Co. Ltd., Qiagen N.V., Exelixis Inc., BeiGene Ltd., RayzeBio Inc., Innovent Biologics Inc., Celsion Corporation
Which emerging trends are set to transform the liver cancer market landscape?
Major companies operating in the liver cancer market are focusing on developing innovative therapy devices, providing transcatheter arterial chemoembolization (TACE), to enhance treatment precision, improve patient outcomes, and reduce side effects. Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure that delivers chemotherapy directly to a liver tumor while blocking its blood supply to enhance treatment effectiveness. For instance, in November 2023, Terumo Corporation, a Japan-based medical technology company, has launched Occlusafe and LifePearl, innovative therapy devices for management of liver cancer. These devices are designed to enhance the management of liver cancer, particularly hepatocellular carcinoma (HCC), which is the most common form of primary liver cancer in India, with over 20,000 new cases reported annually. Occlusafe is part of an advanced therapy called Balloon-TACE (B-TACE), which enhances the precision and effectiveness of TACE by using a balloon to occlude blood flow during the procedure. LifePearl are polyethylene glycol (PEG) embolization microspheres that can be loaded with chemotherapeutic agents.
How do different geographies compare in terms of market share and growth potential in the liver cancer market?
North America was the largest region in the liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/liver-cancer-global-market-report
Which major segments of the liver cancer market are experiencing the fastest growth?
The liver cancer market covered in this report is segmented –
1) By Type: Hepatoblastoma, Intrahepatic Cholangiocarcinoma, Hepatocellular Carcinoma, Fibrolamellar Carcinoma
2) By Stage Of Liver Cancer: Early Stage, Intermediate Stage, Advanced Stage
3) By Treatment: Targeted Therapy, Radiation Therapy, Surgery, Chemotherapy, Immunotherapy
4) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cancer Research Institutes
Subsegments:
1) By Hepatoblastoma: Epithelial Hepatoblastoma, Mixed Epithelial and Mesenchymal Hepatoblastoma
2) By Intrahepatic Cholangiocarcinoma: Mass-forming Cholangiocarcinoma, Periductal Infiltrating Cholangiocarcinoma, Intraductal Growing Cholangiocarcinoma
3) By Hepatocellular Carcinoma: Fibrolamellar Hepatocellular Carcinoma, Conventional Hepatocellular Carcinoma, Scirrhous Hepatocellular Carcinoma, Clear Cell Hepatocellular Carcinoma, Lymphoepithelioma-like Hepatocellular Carcinoma
4) By Fibrolamellar Carcinoma: Classic Fibrolamellar Carcinoma, Mixed Fibrolamellar and Conventional Hepatocellular Carcinoma
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22039
How is the liver cancer market defined, and what are its core characteristics?
Liver cancer is a malignant disease that originates in the liver cells, primarily hepatocytes, and can spread to other organs. It is associated with risk factors such as chronic hepatitis B and C infections, cirrhosis, excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). The disease is often diagnosed at advanced stages, making early detection and treatment crucial for improving survival rates.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
